A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorAthanassiades, A.en
dc.contributor.authorGiannakakis, T.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorOnienaoum, A.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorAndreopoulou, E.en
dc.contributor.authorBamia, C.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorSkarlos, D.en
dc.date.accessioned2015-11-24T19:39:25Z
dc.date.available2015-11-24T19:39:25Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24244
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibiotics, Antineoplastic/*administration & dosage/adverse effectsen
dc.subjectBreast Neoplasms/*drug therapyen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Administration Scheduleen
dc.subjectEpirubicin/*administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectSurvival Analysisen
dc.subjectTreatment Outcomeen
dc.titleA randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group studyen
heal.abstractPURPOSE: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. PATIENTS AND METHODS: From January 1991 until April 1996, 167 patients with ABC were randomized to receive epirubicin (110 mg/m2) either every four (81 patients, group A) or every two weeks (86 patients, group B). Filgrastim (5 micrograms/kg/daily) was administered prophylactically on days 2-12 of each cycle. RESULTS: The two groups were equally balanced in terms of major patient and tumor characteristics. Even though the median cumulative dose of epirubicin was identical in the two groups (651 mg/m2), the median DI of epirubicin was doubled in group B (27.2 vs. 52.9 mg/m2/wk, respectively). The complete response (CR) rate was significantly increased in group B (5%, 95% CI: 0.16%-9.84% vs. 17%, 95% CI: 8.9%-25.08%, P = 0.011), although overall response rates were similar (49% vs. 53%, P = 0.5957). Also, there was no significant difference in the incidence of grade 3-4 toxicity between the two groups. After a median follow-up of 25 months (range, 0.43-43.3+) no significant difference was observed in the duration of response (median, 10 months vs. 8.5 months, P = 0.5130), time to progression (median, 7.2 months vs. 7.4 months, P = 0.2970) or survival (median, 14.6 months vs. 14.9 months, P = 0.4483). Logistic regression analysis showed that performance status was a significant variable for response (P = 0.0068) and multivariate analysis using the Cox proportional hazards model revealed that performance status was significant for survival (P = 0.0049), while the presence of multiple metastases (P = 0.0020) was significant for time to progression. CONCLUSION: Doubling the planned DI of epirubicin monotherapy significantly increases the CR rate but has no influence on time to progression or survival in patients with ABC.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9496386-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/8/12/1213.full.pdf-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1997-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ